First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension

Abstract

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.

Therapeutic strategy in patients with long-lasting essential hypertension with comorbid type 2 diabetes mellitus and obesity

“…The fixed combination definitely reduces the risk of progression (clinical worsening) of the hypertensive patient with T2DM mellitus and obesity history of ineffective BP lowering treatment was investigated. The majority of publications are devoted to the problem of the first-line therapy [10][11][12]; in contrast, we tried to find out better strategies in those patients who were unsuccessful with recommended first-line treatments. Also we tried to evaluate (to measure) exact preferences of single-pill triple regimen over multi-pill format.…”

Ficus Benghalensis Bark Extract Shows Blood Pressure Lowering Effect in Normotensive and Angiotensin II-Induced Hypertensive Rats

“…Renin-angiotensin system (RAS) activation is one of the key contributing factors for hypertension which has been a major cardiovascular disease resulting in significant mortality worldwide [16]. Therefore, modulation of RAS could be a viable therapeutic strategy for managing hypertension.…”

Development of Subcutaneous Implants of Controlled Release Formulations of Carvedilol for Sustained Blood Pressure Reduction in Experimental Models of Hypertension

“…( 14) Despite the recognized importance of the sympathetic nervous system in the development of hypertension, ß-blockers are no longer recommended as first-line treatment due to clinical trial evidence suggesting reduced cardioprotection as a result of their limited effects on central blood pressure and blood pressure variability, and the development of adverse metabolic effects. (15)(16)(17) However, these limitations are typical of conventional ß-blockers, especially atenolol, and do not seem to be extrapolated to vasodilator ß-blockers with pleiotropic action, such as carvedilol. (8) Clinical trial results and evaluations conducted in experimental models of hypertension have estab-lished that chronic treatment with carvedilol is more effective than with atenolol in reducing central blood pressure and blood pressure variability, hemodynamic properties that suggest greater protection from target organ damage associated with hypertension.…”